01—Abstract
Summary
Summary of the 10-K filed February 27, 2009. Cited figures are marked; the original filing is the authoritative source.
Amgen Inc. reported total revenues of $15.0 billiona for the fiscal year ended December 31, 2008, representing a 3% increase over the prior year.
Net income was $4.2 billionb, or $3.90 per diluted share. The company faced significant headwinds, particularly from regulatory and reimbursement developments affecting its erythropoiesis-stimulating agent (ESA) products, including Aranesp® and EPOGEN®. These challenges led to a material adverse impact on Aranesp® sales, especially in the U.S. supportive cancer care setting, and also affected EPOGEN® sales due to revised reimbursement policies.
Despite these challenges, Amgen demonstrated resilience with strong sales growth in ENBREL® and Neulasta®/NEUPOGEN®. The company also made progress in its late-stage product candidate pipeline, notably with denosumab, for which a biologics license application was submitted to the FDA in December 2008. Amgen continued to manage its cost structure through restructuring initiatives, incurring $887 millionc in charges through December 31, 2008, with remaining estimated costs to be incurred in 2009.
02—Key points
Key Highlights
- Total revenues reached $15.0 billion, a 3% increase year-over-year, driven by strong performance in ENBREL® and Neulasta®/NEUPOGEN®.
- Net income was $4.2 billion, or $3.90 per diluted share.
- Aranesp® and EPOGEN® sales experienced a decline primarily due to significant regulatory and reimbursement changes impacting the ESA class.
- The company incurred $887 million in restructuring charges through December 31, 2008, as part of a plan to improve its cost structure.
- Denosumab, a key late-stage product candidate, advanced with an FDA submission for the treatment and prevention of postmenopausal osteoporosis and bone loss.
- Amgen continued its robust share repurchase program, repurchasing $2.3 billion of common stock during 2008.
- The company ended the year with strong liquidity, reporting $9.6 billion in cash, cash equivalents, and marketable securities.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2008filed February 27, 2009Financial Statements
FY2008 against FY2007
| Line item | FY2008FY2007 | Change |
|---|---|---|
| Revenue | $15.00B$14.77B | +1.6% |
| SG&A Expenses | $3.79B$3.36B | +12.7% |
| Operating Expenses | $9.79B$10.79B | −9.3% |
| Operating Income | $5.21B$3.98B | +31.0% |
| Interest Expense | $551.00M$496.00M | +11.1% |
| Net Income | $4.05B$3.08B | +31.6% |
| EPS (Basic) | $3.79$2.76 | +37.3% |
| EPS (Diluted) | $3.77$2.74 | +37.6% |
| Shares Outstanding (Basic) | 1.07B1.12B | −4.2% |
| Shares Outstanding (Diluted) | 1.07B1.12B | −4.3% |
05—Questions
Frequently Asked Questions
What were the main factors impacting Amgen's financial performance in 2008?
Amgen's financial performance in 2008 was influenced by both positive and negative factors. Key drivers of revenue growth included strong sales for ENBREL® and Neulasta®/NEUPOGEN®. However, the company faced significant challenges from regulatory and reimbursement changes impacting its erythropoiesis-stimulating agent (ESA) products, Aranesp® and EPOGEN®, which led to a decline in their sales. Additionally, Amgen incurred substantial restructuring charges and legal settlement expenses.
How did the regulatory issues with ESAs affect Amgen's sales?
Regulatory and reimbursement developments, including safety-related labeling changes and restricted Medicare reimbursement for ESAs, materially and adversely impacted Aranesp® sales, particularly in the U.S. supportive cancer care setting. Similar pressures affected EPOGEN® sales due to revised reimbursement policies and physician behavior changes related to dosing and utilization.
What progress did Amgen make in its product pipeline in 2008?
Amgen made notable progress in its pipeline. Denosumab, a key late-stage product candidate, advanced with the submission of a biologics license application to the FDA in December 2008 for osteoporosis and bone loss indications. The company continued to invest significantly in research and development across various therapeutic areas.
What is Amgen's financial position regarding cash and debt?
Amgen maintained a strong financial position, ending 2008 with $9.6 billion in cash, cash equivalents, and marketable securities. The company reported total debt of $10.2 billion. Amgen indicated that its existing funds and cash generated from operations were sufficient to meet its working capital, capital expenditure, and debt service requirements for the foreseeable future.
06—Continue